

# Biopsy-Confirmed Celiac Disease After COVID-19 Infection

Mahmoud Aryan MD<sup>1</sup>, Chirag Patel MD<sup>2</sup>, Dane Johnson MD<sup>3</sup>, & Amanda Cartee MD<sup>3</sup>

- Tinsley Harrison Internal Medicine Residency Training Program, University of Alabama at Birmingham
  Department of Pathology, University of Alabama at Birmingham
  - 3. Division of Gastroenterology & Hepatology, University of Alabama at Birmingham

#### Background

- Post-COVID gastrointestinal (GI) symptoms are increasingly common in clinical practice and can sometimes overlap with other common, treatable GI disorders, such as Celiac Disease (CeD).
- We present the case of post-COVID GI symptoms subsequently diagnosed with CeD.

### Case Description

- A 28-year-old man with no prior medical history presented with nausea, vomiting, poor appetite, and weight loss after recovery from PCR-confirmed COVID-19 infection.
- He endorsed an unintentional 40pound weight loss with fatigue over 4 months.
- He denied constipation or diarrhea.
- Symptoms did not improve with a proton pump inhibitor trial.
- Family history-was remarkable for a brother with type 1 diabetes


#### Objective Data

- Physical exam was remarkable for obesity, BMI 34.3
- A recent CT abdomen and pelvis was unrevealing.
- Tissue transglutaminase IgA was elevated at 57 U/mL (normal <19 U/mL).</li>
- He had vitamin D, vitamin B12, and folate deficiencies


#### Follow-up

- Symptoms resolved on a gluten free diet.
- Tissue transglutaminase IgA normalized
  (9 U/mL) within 6 months of treatment

#### Workup



Duodenal scalloping and atrophy



Biopsies confirmed CeD, Marsh 3B

## 1 Trovato CM et al. COVID-19 and celiac disease: A pathogenetic hypothesis for a celiac outbreak. International Journal of Clinical Practice. 2021;75(9). 2 Hoffman M et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.

#### Discussion

- Post-COVID symptoms are varied, non-specific, and overlap with other GI conditions.
- There has been a reported increased prevalence of CeD in all age groups during the SARS-CoV-2 pandemic<sup>1</sup>.
- SARS-CoV2 enters mucosal membranes via angiotensin-converting enzyme 2, which is present in the small bowel mucosa<sup>2</sup>.
- Our case highlights that weight loss, and other "red flag" symptoms should prompt further evaluation despite being a common post-COVID symptom.
- We contemplate what role, SARS-CoV-2 could have in disrupting small bowel mucosa integrity, potentially leading to CeD in genetically susceptible individuals.